Foundation Medicine Inc. and Natera Inc. launched an early access program for clinical use of FoundationOne Tracker, a personalized circulating tumor DNA monitoring assay.
FDA has approved for FoundationOne CDx to be used as a companion diagnostic to identify patients with non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) alterations and are appropriate for treatment with EGFR tyrosine kinase inhibitors approved by FDA for this indication.
